<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658890</url>
  </required_header>
  <id_info>
    <org_study_id>CA017-003</org_study_id>
    <secondary_id>2015-004914-79</secondary_id>
    <nct_id>NCT02658890</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread</brief_title>
  <official_title>A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine safety and effectiveness of experimental medication&#xD;
      BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab&#xD;
      in patients with cancers that are advanced or have spread. Pharmacokinetics and&#xD;
      pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab&#xD;
      and Ipilimumab in this patient population will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 22, 2016</start_date>
  <completion_date type="Anticipated">October 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-986205 as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.</measure>
    <time_frame>100 days after the last dose of study therapy</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of BMS-986205 plus nivolumab as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.</measure>
    <time_frame>100 days after the last dose of study therapy</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of BMS-986205 plus both nivolumab and ipilimumab as measured by incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.</measure>
    <time_frame>100 days after the last dose of study therapy</time_frame>
    <description>measured by incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the best overall response (BOR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by CT scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the duration of response (DOR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by CT scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by progression-free survival rates (PFSRs)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by CT scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the best overall response (BOR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by CT scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the duration of response (DOR)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by CT scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by progression-free survival rates (PFSRs)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration at the end of the dosing interval (Ctrough) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at 24 hours (C24) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (T-HALF) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent renal clearance (CLR/F) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of terminal phase (Vz/F) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss/F) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index (AI) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent urinary recovery (%UR) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by urine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent urinary recovery over 24 hours(%UR24) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by urine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax) of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(0-T)] of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)] of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(INF)] of BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) response to Nivolumab in combination with BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by immunoassay and liquid chromatography- mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) response to Ipilimumab in combination with BMS-986205</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>measured by immunoassay and liquid chromatography- mass spectrometry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">630</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Combination Therapy (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS 986205 + Nivolumab specified dose at specified intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS 986205 + Nivolumab specified dose at specified intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy 2 (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS 986205 + both Nivolumab and ipilimumab specified dose at specified intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986205</intervention_name>
    <arm_group_label>Combination Therapy (Dose Escalation)</arm_group_label>
    <arm_group_label>Combination Therapy (Dose Expansion)</arm_group_label>
    <arm_group_label>Combination Therapy 2 (Dose Expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Combination Therapy (Dose Escalation)</arm_group_label>
    <arm_group_label>Combination Therapy (Dose Expansion)</arm_group_label>
    <arm_group_label>Combination Therapy 2 (Dose Expansion)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>ANTI-PD1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Combination Therapy 2 (Dose Expansion)</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>ANTI-CTLA-4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation,&#xD;
        please visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  During dose escalation, subjects with advanced solid tumors that have progressed&#xD;
             following at least one standard regimen&#xD;
&#xD;
          -  During cohort expansion, subjects with advanced cancer that either have received at&#xD;
             least one prior therapy or are treatment naive, depending on the specified tumor type&#xD;
&#xD;
          -  Subjects must have measurable disease&#xD;
&#xD;
          -  Subject must consent to provide previously collected tumor tissue and a tumor biopsy&#xD;
             during screening.&#xD;
&#xD;
          -  At least 4 weeks since any previous treatment for cancer&#xD;
&#xD;
          -  Must be able to swallow pills or capsules&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or chronic autoimmune diseases&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency&#xD;
             virus (HIV), or acquired immune deficiency syndrome (AIDS)&#xD;
&#xD;
          -  Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C&#xD;
             antibody (except for subjects with hepatocellular carcinoma)&#xD;
&#xD;
          -  Active central nervous system (CNS) metastases and CNS metastases as the only sites of&#xD;
             disease&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Kinghorn Cancer Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2146</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille CEDEX</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu - Chu De Nantes</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale Tumori Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano MI</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Badan Wczesnych Faz</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Linrodostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

